A ten -year study confirms the effectiveness of two -week prostate radiotherapy

Prostate cancer is the most commonly diagnosed cancer in men around the world, which is over 1.4 million new cases. For many patients, radiation therapy is a standard treatment option that offers results comparable to surgery, especially in the case of the disease located. As an outpatient procedure, it allows men to keep most of the daily routine during treatment. However, traditional radiotherapy schedules usually include several weeks, which can be burdensome for patients and put pressure on healthcare structures and radiotherapy.

The main clinical examination (HYPO-RT-PC) showed that a much shorter course of radiotherapy of located prostate cancer is just as safe and effective as a traditional eight-weekly schedule-nave 10 years after treatment. The discoveries, presented in Estro 2025, the annual Congress of the European Society of Radiotherapy and Oncology, give both patients and doctors more confidence in choosing this short approach, also called “Ultra Hypo-Frained Radiotherapy”.

The study, conducted by scientists in Sweden, showed that providing precise radiation therapy for only two and a half weeks is equally effective in overcoming prostate cancer as a standard eight -week approach. Ten years after treatment, both options caused similar disease control indicators and survival.

“These long-term findings confirm the previous 5 years of study results, which shows that the supply of a smaller, higher dose in a shorter period works just as well as the standard approach-not only theoretically, but in clinical practice in the real world,” said connections with Nilsson, senior radiation physics, and AdalSteinn Gunnlaugsson radiation radiation radiation. SCHOOL HOST HOSPITAL AND LUND University, Sweden.

“For patients, this means less disturbing everyday life and potentially lower health care costs – without prejudice for results and safety.”

About the study

1,200 men with intermediate prostate cancer to high risk have a large clinical examination of phases III. Participants were randomly assigned to receive:
• Short -term radiotherapy: 42.7 Gray (GY) supplied in 7 sessions within 2.5 weeks
• Standard radiotherapy: 78.0 GY supplied in 39 sessions within 8 weeks
Scientists assessed the survival, recurrence of cancer and side effects associated with treatment, including urine and intestinal symptoms.

Key results after 10 years:

• Free survival from failure (no return on cancer or the need for additional treatment): 72% in the short-challenge group VS 65% in the standard group
• General experience: 81% for a short vs 79% rate for the standard
• Specific mortality for prostate cancer: 4% in both groups
• Side effects: The symptoms of urine and intestines were similar in both groups, and most of them were mild to moderate.

“”, Added Dr. Camilla Thellenberg-Karlsson, at the Umeå University, who presented the results at the meeting in Estro.

Implications for carcinoma

Prostate cancer is one of the most common cancers in men, and radiation therapy remains a key treatment. These results show how modern radiotherapy approaches can make treatment more efficient, available and patient -friendly – without devoting effectiveness or safety.

Professor Matthias Gukenberger, president of Estro, added: “Shorter treatment schedules mean that patients can return to a normal life faster.

“Shortening the treatment time to just two and a half weeks is an important win for both patients and healthcare systems.

“This study is an example of influential research practices that we proudly present on Estro 2025.”